Literature DB >> 7846212

EEG alterations in patients treated with clozapine in relation to plasma levels.

C Haring1, C Neudorfer, J Schwitzer, M Hummer, A Saria, H Hinterhuber, W W Fleischhacker.   

Abstract

It is well known that psychotropic drugs can induce EEG alterations. Dose dependence seems established; however, there are no data concerning the impact of plasma levels. The authors investigated the influence of clozapine plasma levels on the frequency of EEG alterations. Data from 29 inpatients (18 male, 11 female, 31.7 +/- 10.2 years) receiving clozapine in a dose range between 25 and 600 mg were collected prospectively. There was no psychotropic or anticholinergic comedication. All patients had normal EEGs before taking clozapine. Fifteen patients showed pathological changes (group 2) and 14 no changes (group 1). Discriminant analysis showed that EEG changes are dependent on plasma levels (P = 0.0009, plasma levels in group 1 mean 81.6 ng/ml, +/- SD 64.6, in group 2 235.7 ng/ml, +/- 169.8). A total of 72.4% of the patients were correctly classified as having either pathological EEG changes or none by this analysis. Variables such as dose, age, sex, weight and duration of treatment were not statistically relevant. It can therefore be suggested that clozapine plasma levels are a valid indicator for the appearance of electrophysiological reactions.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7846212     DOI: 10.1007/bf02245449

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  19 in total

1.  Influence of patient-related variables on clozapine plasma levels.

Authors:  C Haring; W W Fleischhacker; P Schett; C Humpel; C Barnas; A Saria
Journal:  Am J Psychiatry       Date:  1990-11       Impact factor: 18.112

Review 2.  Leponex--associated granulocytopenia: a review of the situation.

Authors:  P Krupp; P Barnes
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

3.  Clozapine plasma levels determined by high-performance liquid chromatography with ultraviolet detection.

Authors:  C Haring; C Humpel; B Auer; A Saria; C Barnas; W Fleischhacker; H Hinterhuber
Journal:  J Chromatogr       Date:  1988-06-24

4.  EEG profile studies of clozapine in volunteers and psychiatric patients.

Authors:  M Fink; P Irwin; P Weinhold
Journal:  Pharmakopsychiatr Neuropsychopharmakol       Date:  1979-03

5.  Relationship between fluphenazine plasma concentration and electroencephalographic alterations.

Authors:  T A Robert; E A Daigneault; A N Hagardorn
Journal:  Commun Psychopharmacol       Date:  1978

6.  Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine.

Authors:  J Kane; G Honigfeld; J Singer; H Meltzer
Journal:  Arch Gen Psychiatry       Date:  1988-09

7.  EEG profile and behavioral changes after a single dose of clozapine in normals and schizophrenics.

Authors:  J Roubicek; I Major
Journal:  Biol Psychiatry       Date:  1977-10       Impact factor: 13.382

8.  Relationship between plasma-levels of chlorpromazine and effects on EEG and evoked potentials in healthy volunteers.

Authors:  S Laurian; P K Le; P Baumann; M Perey; J M Gaillard
Journal:  Pharmacopsychiatria       Date:  1981-11

9.  Tolerability and therapeutic effect of clozapine. A retrospective investigation of 216 patients treated with clozapine for up to 12 years.

Authors:  U Juul Povlsen; U Noring; R Fog; J Gerlach
Journal:  Acta Psychiatr Scand       Date:  1985-02       Impact factor: 6.392

10.  Clozapine and seizures.

Authors:  E Haller; R L Binder
Journal:  Am J Psychiatry       Date:  1990-08       Impact factor: 18.112

View more
  21 in total

Review 1.  Predictors and markers of clozapine response.

Authors:  Carmen Chung; Gary Remington
Journal:  Psychopharmacology (Berl)       Date:  2005-02-17       Impact factor: 4.530

Review 2.  Tolerability of atypical antipsychotics.

Authors:  C Stanniland; D Taylor
Journal:  Drug Saf       Date:  2000-03       Impact factor: 5.606

Review 3.  Factors associated with response to clozapine in schizophrenia: a review.

Authors:  Takefumi Suzuki; Hiroyuki Uchida; Koichiro Watanabe; Haruo Kashima
Journal:  Psychopharmacol Bull       Date:  2011

Review 4.  Seizure associated with clozapine: incidence, etiology, and management.

Authors:  Andrew M Williams; Susie H Park
Journal:  CNS Drugs       Date:  2015-02       Impact factor: 5.749

5.  Extrapyramidal side effects of clozapine and haloperidol.

Authors:  M Kurz; M Hummer; H Oberbauer; W W Fleischhacker
Journal:  Psychopharmacology (Berl)       Date:  1995-03       Impact factor: 4.530

Review 6.  Clozapine plasma level monitoring: current status.

Authors:  T B Cooper
Journal:  Psychiatr Q       Date:  1996

7.  Clozapine-related EEG changes and seizures: dose and plasma-level relationships.

Authors:  Seema Varma; Delia Bishara; Frank M C Besag; David Taylor
Journal:  Ther Adv Psychopharmacol       Date:  2011-04

8.  Subtype specificity of gamma-aminobutyric acid type A receptor antagonism by clozapine.

Authors:  E R Korpi; G Wong; H Lüddens
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-10       Impact factor: 3.000

Review 9.  Clozapine and therapeutic drug monitoring: is there sufficient evidence for an upper threshold?

Authors:  Gary Remington; Ofer Agid; George Foussias; Larissa Ferguson; Krysta McDonald; Valerie Powell
Journal:  Psychopharmacology (Berl)       Date:  2012-11-22       Impact factor: 4.530

10.  Clozapine serum levels and side effects during steady state treatment of schizophrenic patients: a cross-sectional study.

Authors:  O V Olesen; K Thomsen; P N Jensen; C H Wulff; N A Rasmussen; C Refshammer; J Sørensen; M Bysted; J Christensen; R Rosenberg
Journal:  Psychopharmacology (Berl)       Date:  1995-02       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.